Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5665390 | Autoimmunity Reviews | 2017 | 5 Pages |
Recently the importance of CXCL10 in the pathogenesis of non-segmental vitiligo (NSV) and autoimmune thyroid disorders (AITD) has been shown. No data are present about chemokines CXCL10 (Th1 prototype) and CCL2 (Th2 prototype) circulating levels in NSV patients with/without thyroiditis (AT).Serum CXCL10 and CCL2 have been measured in 50 consecutive NSV patients, in 40 consecutive patients with NSV and AT (NSVÂ +Â AT), in 50 sex- and age-matched controls without AT (control 1) and in 40 sex- and age-matched patients with AT without NSV (control 2).Serum CXCL10 levels were significantly higher in control 2, than in control 1 (PÂ =Â 0.001; ANOVA). NSV patients have serum CXCL10 levels significantly higher than control 1, or control 2 (PÂ =Â 0.001). NSVÂ +Â AT patients have serum CXCL10 levels higher than control 1, or 2 (PÂ <Â 0.001), and than NSV (PÂ =Â 0.01).In conclusion, we first demonstrate high serum CXCL10 in NSV patients, overall in presence of AT and hypothyroidism, suggesting the importance of a common Th1 immune response in their immune-pathogenesis. To evaluate if serum CXCL10 might be used as a clinical marker of NSV and/or AT further studies are needed.